Malvern Instruments has launched the Zetasizer Nano ZSP, bringing unique protein measurement and novel microrheology capabilities to this range of dynamic light scattering (DLS) systems. The high specification Zetasizer Nano ZSP delivers enhanced sensitivity and comes with advanced software that drives the two measurement types.
Like other systems in the range, the Zetasizer Nano ZSP is a single, compact unit. It shares the simplicity and ease of use that have made Zetasizer Nano systems a firm favorite in industry and academia for almost a decade. Where the Zetasizer Nano ZSP stands apart, however, is in its unique performance specifications for both size and zeta potential measurement. One of the most significant applications being the measurement of the zeta potential, or electrophoretic mobility, of proteins. This process is further simplified by the inclusion of a protein mobility measurement type in the software that controls data acquisition, guiding the user through the measurement and assesses and reports on data quality. The protein mobility measurement package is included with the Zetasizer Nano ZSP instrument as standard.
As well as the suite of protein-specific features, this version of Zetasizer software, launched together with the Zetasizer Nano ZSP, enables a a new type of measurement on the instrument – microrheology. This DLS-based optical technique allows rheological characterization of weakly-structured and highly strain-sensitive materials using only microliter sample volumes. Amongst its applications are measuring the viscosity of polymer and protein solutions and determining the onset of protein aggregation.
Malvern’s extended Zetasizer family now includes the full Zetasizer Nano range of systems for characterizing size, molecular weight and zeta potential measurement; the Zetasizer APS for automated protein size measurements in multiwell plates; and the Zetasizer µV designed for protein size and molecular weight measurements in both cuvette and chromatography modes (for example, in combination with a GPC/SEC system).
Filed Under: Drug Discovery
